Nurix Therapeutics (NRIX) Receivables - Other (2020 - 2026)
Nurix Therapeutics (NRIX) has disclosed Receivables - Other for 7 consecutive years, with $2.4 million as the latest value for Q1 2026.
- Quarterly Receivables - Other fell 65.71% to $2.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Feb 2026, down 65.71% year-over-year, with the annual reading at $5.0 million for FY2025, 0.0% changed from the prior year.
- Receivables - Other for Q1 2026 was $2.4 million at Nurix Therapeutics, down from $5.0 million in the prior quarter.
- The five-year high for Receivables - Other was $7.0 million in Q1 2025, with the low at $600000.0 in Q2 2024.
- Average Receivables - Other over 5 years is $2.9 million, with a median of $2.0 million recorded in 2022.
- The sharpest move saw Receivables - Other skyrocketed 300.0% in 2023, then crashed 86.67% in 2024.
- Over 5 years, Receivables - Other stood at $1.0 million in 2022, then surged by 300.0% to $4.0 million in 2023, then grew by 25.0% to $5.0 million in 2024, then changed by 0.0% to $5.0 million in 2025, then plummeted by 52.0% to $2.4 million in 2026.
- According to Business Quant data, Receivables - Other over the past three periods came in at $2.4 million, $5.0 million, and $1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.